Compare e l f Beauty Inc (ELF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Recursion Pharmaceuticals Inc — how do they compare? e l f Beauty Inc trades at $76.34 (market cap $4.37B), while Recursion Pharmaceuticals Inc trades at $3.2 (market cap $1.75B). The key difference: e l f Beauty Inc is far larger — about 2.5× Recursion Pharmaceuticals Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ELF | RXRX | |
|---|---|---|
Market Cap | $4.37B | $1.75B |
Sector | Technology | Health |
52-Week High | $146.67 | $6.79 |
52-Week Low | $49.57 | $2.84 |
Enterprise Value | $5.00B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $76.11, up 5.34% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins remain thin at 1.61%. Recent analyst coverage is mixed with 46% buy ratings and consensus target of $74.42, slightly below current price. The company demonstrates solid operational cash flow of $133.84M and maintains a healthy balance sheet with $148.69M cash.
Outlook remains positive with continued double-digit sales growth targets, though elevated P/E ratio of 168.68 presents valuation concerns. Key risks include tariff exposure and core brand momentum challenges. Institutional sentiment leans bullish with recent price momentum supported by earnings outperformance and strategic expansion into skincare categories.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
